Australia - English - Department of Health (Therapeutic Goods Administration)

emergo asia pacific pty ltd t/a emergo australia -

Australia - English - Department of Health (Therapeutic Goods Administration)

emergo asia pacific pty ltd t/a emergo australia - 46102 - irrigation tubing set, general purpose - the single channel liquid-flow tube is an accessory to the ultrasonic osteotomy surgical system that is used to guide the irrigant, protect the surgeon, and used for cooling down the handpiece cutting tip and washing the working surface.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 86.475 mg (equivalent: dabigatran etexilate, qty 75 mg) - capsule, hard - excipient ingredients: purified water; hypromellose phthalate; hyprolose; dichloromethane; tartaric acid; ethanol; butylated hydroxytoluene; povidone; purified talc; citric acid monohydrate; isopropyl alcohol; microcrystalline cellulose; macrogol 600; titanium dioxide; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer; hypromellose; sunset yellow fcf; macrogol 8000 - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

emergo asia pacific pty ltd t/a emergo australia - 44772 - tubing set, irrigation pump - hk surgical infiltration tubing is intended for use as a pathway for surgical fluids between the irrigation source and the operative site. the infiltration tubing has a clear drip chamber and silicone pressure tube insert for use in peristaltic infiltration pumps.

Australia - English - Department of Health (Therapeutic Goods Administration)

emergo asia pacific pty ltd t/a emergo australia - 47625 - irrigation/aspiration system tubing set - the pump set is intended to deliver a high pressure sterile physiological saline stream to catheters to remove/aspirate fluid, and break soft emboli and thrombi from the coronary and peripheral vasculature when used in combination with saline drive units (sdus).

Australia - English - Department of Health (Therapeutic Goods Administration)

emergo asia pacific pty ltd t/a emergo australia - 47625 - irrigation/aspiration system tubing set - the applicators are to be used with the body-jet devices manufactured by human med in water-jet assisted liposuctions for the purpose of harvesting fat tissue that may be used for autologous fat transfer in aesthetic and reconstructive plastic surgeries.

Australia - English - Department of Health (Therapeutic Goods Administration)

emergo asia pacific pty ltd t/a emergo australia - 47625 - irrigation/aspiration system tubing set - the sterile tubing kit connects an aspiration catheter to a dedicated suction pump.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 86.475 mg (equivalent: dabigatran etexilate, qty 75 mg) - capsule, hard - excipient ingredients: purified water; hypromellose phthalate; tartaric acid; butylated hydroxytoluene; hyprolose; microcrystalline cellulose; dichloromethane; purified talc; isopropyl alcohol; macrogol 600; citric acid monohydrate; ethanol; povidone; titanium dioxide; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer; macrogol 8000; hypromellose; sunset yellow fcf - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 86.475 mg (equivalent: dabigatran etexilate, qty 75 mg) - capsule, hard - excipient ingredients: citric acid monohydrate; butylated hydroxytoluene; dichloromethane; microcrystalline cellulose; ethanol; povidone; tartaric acid; macrogol 600; purified talc; isopropyl alcohol; hyprolose; hypromellose phthalate; purified water; titanium dioxide; hypromellose; sunset yellow fcf; macrogol 8000; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dabigatran etexilate mesilate, quantity: 86.475 mg (equivalent: dabigatran etexilate, qty 75 mg) - capsule, hard - excipient ingredients: ethanol; microcrystalline cellulose; purified talc; isopropyl alcohol; dichloromethane; hypromellose phthalate; macrogol 600; butylated hydroxytoluene; povidone; citric acid monohydrate; purified water; hyprolose; tartaric acid; titanium dioxide; macrogol 8000; hypromellose; sunset yellow fcf; polyvinyl alcohol; macrogol 3350; sodium bicarbonate; methacrylic acid copolymer - dabigatran is indicated for prevention of venous thromboembolic events in adult patients who have undergone major orthopaedic surgery of the lower limb (elective total hip or knee replacement). prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and for the prevention of recurrent dvt and pe in adults.